Tag: GlobeNewswire

AI, capacity, suppliers, and skills are becoming the resources that define who wins in manufacturing next year, and access beyond the factory walls is the key to unlocking them

• Manufacturing’s AI payoff is upstream: Manufacturers see the biggest impact in manufacturability, costing, and quality control, not on the factory floor.
• America’s idle industrial capacity is hiding in small shops: Smaller manufacturers have far more room to run than larger ones, if they can meet certification requirements.
• Supplier optionality is becoming a competitive advantage: With prices rising and pushback low, buyers are leaning on supplier access instead.
• Manufacturing needs skills, not just headcount: AI and automation operators are now the hardest role to fill, and higher pay alone isn’t solving it.

NORTH BETHESDA, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ:XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today released its second annual Manufacturing Outlook report, a forward-looking analysis of the forces shaping the manufacturing industry for 2027.

The Manufacturing Advantage is Shifting
The 2027 Manufacturing Outlook—based on proprietary research with manufacturing executives across the U.S., along with insights from Xometry and external subject matter experts—points to a shift in the manufacturing advantage, traditionally built around a company’s assets. Increasingly, what matters is what a company can access: capacity beyond its own walls, qualified suppliers when conditions change, and AI-driven intelligence that extends the expertise of its existing workforce.

“AI is moving earlier into the manufacturing process, and the skills our industry needs are moving with it,” said Sanjeev Singh Sahni, CEO of Xometry. “There’s plenty of manufacturing capacity in the U.S. to meet the growing demand for parts from robotics and physical AI to defense, much of it in smaller shops running below full utilization. The challenge is that these products depend on parts made from different suppliers, assembled in stages, and most supply chains weren’t built for that many handoffs. Solving that takes access to the right partners at every step. This year’s Manufacturing Outlook confirms what we’re seeing across our own network: the companies that adapt fastest are the ones treating access, not just assets, as their competitive edge.”

Using the insights from Xometry and survey responses from manufacturing executives, four trends were identified that will shape global manufacturing in 2027:

1. Manufacturing’s AI payoff is upstream. Manufacturers expect AI to have its greatest impact on manufacturability and costing (51%) and quality control (47%), well ahead of production execution on the factory floor (32%). ROI from AI investment is climbing: 57% of manufacturers report significant returns, up from 44% a year ago. But the report also surfaces a gap: much of that reported ROI is coming from general-purpose AI tools that offer no grounding in real pricing, capacity, or production data. The advantage is shifting from simply using AI to accessing AI that’s grounded in real manufacturing data. “When it comes to manufacturing, AI adoption has become the baseline, not the milestone. The real question is what gets built on top of it,” said Vaidy Raghavan, Chief Technology Officer of Xometry.
2. America’s idle industrial capacity is hiding in small shops. Smaller manufacturers have significantly more room to run than larger ones: 44% of manufacturers under $50 million in revenue are operating below 70% capacity, compared with just 16% of manufacturers above $100 million. Certifications are the gateway to unlocking that capacity for higher-value work. In aerospace and defense, 42% of manufacturers rank compliance as a top obstacle to winning new business.
3. Supplier optionality is becoming a competitive advantage. Procurement teams can negotiate price, but they can’t control many of the forces driving it: material costs, tariffs, and labor are pushing 94% of manufacturers to raise prices again in 2027, with only about 20% reporting meaningful pushback from buyers this year. That puts more weight on the levers buyers can control, including where they source, how a part is made, which qualified suppliers can take the work, and what alternatives are available when conditions change. “Procurement teams need to rethink how they manage the supply chains. Increasingly the solution is access to a network across multiple regions that you can leverage as you need and when you need it,” said Oscar Lovera, Chief Operations Officer of Xometry.
4. Manufacturing needs skills, not just headcount. AI and automation operators have become manufacturing’s hardest role to fill, ahead of quality engineers, maintenance technicians, and CNC programmers. Higher pay alone isn’t solving it: a quarter of manufacturers say raising pay produced no meaningful improvement in hiring or retention, and larger companies are having far more success with it than smaller ones. The gap is pushing manufacturers to rethink which skills they need to build in-house versus access externally—through training partnerships, automation, or outside expertise—when the work demands it.

“The opportunity heading into 2027 is to connect more of America’s manufacturing capacity to the companies that need it. The shops that move fastest to make their capacity visible and their credentials current are the ones who win the work,” said Silpa Gollapalli, SVP of Commercial and leader of the Partner Network at Xometry.

Download the full 2027 Manufacturing Outlook report.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet^® industrial sourcing platform, and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their businesses and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com or follow Xometry on LinkedIn.

Media Contact
Lauran Cacciatori
VP Communications
773-610-0806
lauran.cacciatori@xometry.com

Investor Contact
Shawn Milne
VP Investor Relations
240-335-8132
shawn.milne@xometry.com

Industrial firms across Europe are turning to AI-powered networks for manufacturing capacity, quality proof, and specialised engineering skills

MUNICH, Oct. 01, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today released its EMEA Manufacturing Outlook, a forward-looking analysis of the forces shaping the manufacturing industry for 2027. The report draws on a survey of 200 manufacturing executives in France and Germany, benchmarked against 150 executives in the U.S.

The findings highlight that while European manufacturing order books remain strong, companies pulling ahead in 2027 are those extending their reach beyond their own shop floor to tap external capacity, verified quality, and technical expertise on demand.

“Resilience is about choice,” said Oscar Lovera, Chief Operations Officer at Xometry. “Market conditions shift constantly, whether it’s tariffs, geopolitical moves, or capacity constraints. The manufacturers who stay ahead are those who secure flexible options long before they need to use them.”

Key Takeaways from the 2027 EMEA Manufacturing Outlook:

• Manufacturing’s AI Payoff Is Upstream. The highest returns on AI occur before production begins. European manufacturers are finding that targeted application in pricing, quoting, and automated DFM reviews outweighs total spend. This is evidenced by France achieving a 60% ROI on modest outlays, compared to Germany’s 41% ROI despite leading the region in overall investment.
• Europe’s Manufacturing Capacity Is Hiding in Small Shops. Europe and the U.S. operate at similar overall capacity rates (~76% in Europe vs 77% in the U.S.), but European spare capacity is heavily concentrated in smaller suppliers. 37% of European manufacturers with under €50M in revenue operate below 70% capacity. Regulatory requirements such as CBAM and the EU AI Act make pre-qualified digital networks essential for unlocking idle machine time.
• Supplier Optionality Is the New Sourcing Advantage. European manufacturers raised prices just as often as U.S. firms, but faced far less pushback leading to lost business (11% in France and 17% in Germany vs 20% in the U.S.). European buyers accept price adjustments because they prioritise risk reduction and certainty over finding the cheapest quote, paying strong premiums for verified quality and DFM support.
• Manufacturing Needs Skills, Not Just Headcount. The labour challenge across Europe is a specialisation deficit rather than a simple headcount issue. Demand remains heavily concentrated in specialised technical roles like CNC and CAM programmers (49% in France, 44% in Germany). While higher wages help attract talent, pay alone cannot resolve structural shortages, leading top firms to access specialised skills on demand.

“Price matters, but confidence is what closes the deal today,” said Marc Somsen, Vice President of Sales EMEA at Xometry. “Whether it’s DFM support for complex designs, guaranteed part quality, or lead times you can trust, buyers want certainty. The real advantage comes from giving them that operational confidence alongside fair, transparent pricing.”

Download the full 2027 EMEA Manufacturing Outlook.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet^® industrial sourcing platform, and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their businesses and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com, xometry.eu, or follow Xometry on LinkedIn.

Media Contact
Lauran Cacciatori
VP Communications
773-610-0806
lauran.cacciatori@xometry.com

Investor Contact
Shawn Milne
VP Investor Relations
240-335-8132
shawn.milne@xometry.com

Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program

OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resistance and the continued advancement of the Phase 2 DURIPANC clinical trial (“DURIPANC”).

Recent coverage includes:

• Med World News: AIM ImmunoTech’s Ampligen Program Targets One of Pancreatic Cancer’s Hardest Barriers
• Pharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting Immune Resistance in Pancreatic Cancer

Pancreatic cancer remains one of the most difficult cancers to treat, in part because of an immunosuppressive tumor microenvironment that can limit the effectiveness of immune-based therapies. Recent features have examined Ampligen’s potential to help address this challenge through its immune-modulating activity and the rationale for evaluating the drug in combination with checkpoint inhibition.

AIM successfully concluded a Netherlands-approved Named Patient Program (“NPP”) in which 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment, with highly encouraging findings of Overall Survival, safety and improved Quality of Life. Ampligen is also being evaluated in combination with AstraZeneca’s Imfinzi® (durvalumab) in the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, with interim reports of immune system changes that suggest a coordinated activation of innate and adaptive responses, and all while the combination therapy is reported as being well-tolerated and patients consistently report a high Quality of Life throughout treatment. The study has completed final Ampligen dosing, representing an important clinical milestone as the program advances toward topline results expected in the first quarter of 2027.

“The recent media attention around Ampligen reflects the important scientific rationale behind our pancreatic cancer strategy, supported by the meaningful clinical progress we have made with DURIPANC,” said AIM Chief Executive Officer Thomas K. Equels. “With DURIPANC final Ampligen dosing complete and topline results expected in the first quarter of 2027, we are approaching an important inflection point for the program. We believe that the NPP data combined with the upcoming DURIPANC data – including exploratory biomarker analyses that may help AIM to better understand patient response – will provide important insight into Ampligen’s potential role in metastatic pancreatic cancer and help inform the design of a planned pivotal clinical trial.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address immune resistance in pancreatic cancer through its immune-modulating activity; the potential of Ampligen in combination with AstraZeneca’s Imfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing and outcome of the DURIPANC topline results; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Application represents an important step in supporting reimbursement

Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026

ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for LYTENAVA.

The submission advances Outlook Therapeutics’ U.S. commercialization and market access strategy for LYTENAVA, the only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The Company remains on track for a U.S. commercial launch before the end of 2026 and is focused on supporting broad market access, reimbursement and practice readiness for LYTENAVA.

“This submission represents a critical step toward securing a permanent, product-specific J-code for LYTENAVA and establishing a clear and consistent reimbursement pathway for U.S. retina practices,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “A permanent J-code would streamline billing, reduce administrative burden and support broader practice adoption and patient access. We remain focused on executing across market access, reimbursement, commercial readiness and supply ahead of our planned U.S. launch before the end of 2026.”

HCPCS Level II codes are standardized codes used to identify products, supplies and certain services for billing purposes. CMS maintains the HCPCS Level II code set and reviews applications for drugs and biologicals on a quarterly basis. Permanent J-codes are used by government and commercial payers to facilitate billing and reimbursement for physician-administered treatments.

The submission of an HCPCS Level II application does not guarantee that CMS will assign a permanent, product-specific J-code. The assignment of a J-code is separate from coverage and payment determinations and does not guarantee coverage or reimbursement by Medicare or any other payer.

About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, LYTENAVA (bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA. LYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of adults with wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Important Safety Information and Indication

LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

Contraindications

LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Warnings and Precautions

Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Adverse Reactions

The most common adverse reactions (≥1%) reported in patients receiving LYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). These are not all the possible side effects of LYTENAVA.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).

Please see the full U.S. Prescribing Information for LYTENAVA here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements.” All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

Retail turnover (including VAT) of Apranga Group amounted to EUR 34.6 million in September 2026 and increased by 10.9% compared to September 2025.

The retail turnover (including VAT) of Apranga Group totalled EUR 108.5 million in Q3 2026 and increased by 8.8% year-on-year. In Q3 2026, the retail turnover of the Group in Lithuania increased by 10.8%, in Latvia increased by 6.8% and in Estonia increased by 4.5% year-on-year.

In January through September 2026, the retail turnover of Apranga Group (including VAT) totalled EUR 290.8 million and increased by 9.4% year-on-year.

In January through September 2026, the retail turnover of Apranga Group in Lithuania amounted to EUR 178.5 million and increased by 11.4% year-on-year. In the same period the retail turnover of the Group in Latvia reached EUR 72.5 million and increased by 6.4%, whereas in Estonia amounted to EUR 39.8 million and also increased by 6.4% year-on-year.

In 9 months of 2026, Apranga Group opened 6 new stores, renovated 5 stores, out of which 3 were enlarged and closed 3 stores.

Currently, the Apranga Group operates the chain of 174 stores (103 in Lithuania, 44 in Latvia, and 27 in Estonia) with a total area of 93.7 thousand sq. m., or by 1.1% more than a year ago.

Rimantas Perveneckas
„Apranga“ Group General Manager
+370 5 2390801

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study

Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson’s Disease and Movement Disorders 2026 taking place October 4-8, 2026 in Seoul, Korea.

“We are pleased to see LX2006 featured at MDS 2026 through an oral presentation by Dr. Zesiewicz,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics. “The presentation will continue to highlight the encouraging neurologic improvements observed in patients treated with LX2006, including new analyses of mFARS subscores, complementing the cardiac benefits reported to date. Together, these findings continue to build a compelling clinical profile for LX2006 and reinforce its potential to meaningfully address the multisystem burden of Friedreich ataxia.”

Oral Presentation Details:

Session: Dystonia, Functional / Drug-Induced / Autoimmune Movement Disorders, and Pediatric / Rare Neurometabolic / Paroxysmal Movement Disorders
Title: Intravenous AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia: Early Neurologic Assessment from Two Phase 1 and 2 Studies
Presenter: Dr. Theresa Zesiewicz, University of South Florida
Date/Time: October 7^th, 12:30p.m. KST
Session Location: Conference Room E5, 3rd Floor
Presentation Number: OPP10-A

The full abstract is available on the MDS Congress website.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

About LX2006
LX2006 is an AAV-based gene therapy candidate for the treatment of FA cardiomyopathy, the leading cause of death in individuals with FA which affects approximately 5,000 people in the United States. LX2006 is designed to systemically deliver a functional frataxin (FXN) gene to promote the expression of the frataxin protein and restore mitochondrial function in myocardial cells. LX2006 is currently being evaluated in SUNRISE-FA 2, a Phase 2 registrational trial (NCT07721025) and continues in long-term follow up in the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the Weill Cornell Medicine investigator-initiated Phase 1A trial (NCT05302271). LX2006 has been granted Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, admitted into the FDA CMC Development and Readiness Pilot (CDRP) program, and granted orphan medicinal product designation by the European Commission.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, and the timing and likelihood of potential regulatory approval. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026 and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

Annual sales to the customer expected to exceed US$30 million in each of 2027 and 2028

DALIAN, China, Oct. 01, 2026 (GLOBE NEWSWIRE) — CBAK Energy Technology Limited (NASDAQ: CBAT) (“CBAK Energy” or the “Company”), a China-based lithium-ion battery manufacturer and energy solutions provider, today announced that it has agreed on a battery supply framework with a European blue-chip technology company serving automotive and industrial markets worldwide (the “European Customer”). The Company expects orders to be placed in stages under the framework.

The European Customer chose CBAK Energy for its battery technology, manufacturing experience and ability to meet the customer’s requirements for performance and consistent quality.

Shipments and Sales Outlook

As of September 27, 2026, cumulative orders from the European Customer had exceeded US$4.5 million, and CBAK Energy expects the total to continue to grow.

The Company expects annual sales from its current business with the European Customer to exceed US$30 million in each of 2027 and 2028.

New Product Development

The cooperation also includes a new, higher-capacity cell now under development, with commercial deliveries expected to begin in 2027. Sales of this cell are not included in the annual estimates above. The Company believes there are currently few comparable products on the market and expects this cell to lead to larger orders and a long-term supply relationship.

“The framework is in place, and we are confident that more orders will follow,” said Zhiguang Hu, Chief Executive Officer of CBAK Energy. “We have begun supplying the customer and expect sales to increase in the coming years. Our technology and manufacturing experience were key to winning this business. We expect to start commercial deliveries of the higher-capacity cell in 2027 and believe it can generate larger orders over a longer period.”

CBAK Energy does not name the European Customer, subject to mutual agreement.

About CBAK Energy

CBAK Energy Technology Limited (NASDAQ: CBAT) is a China-based company that develops, manufactures and sells high-power lithium-ion and sodium-ion batteries, as well as materials used in high-power lithium-ion batteries. It has battery cell production, research and development, and sales operations in Nanjing, Dalian and Shangqiu, with research and development centers in Nanjing and Dalian. Its raw materials business is based in Shaoxing. The Company’s products serve electric vehicles, light electric vehicles, energy storage systems and other high-power applications. In January 2006, CBAK Energy became the first Chinese lithium battery manufacturer to be listed on the Nasdaq Stock Market.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include expectations about future orders and sales under the battery supply framework; estimated annual sales for 2027 and 2028; the development, qualification and expected 2027 commercial deliveries of the higher-capacity cell; future order values and the duration of the customer relationship; and possible disclosure of the customer’s identity. Words such as “expect,” “estimate,” “anticipate,” “believe,” “plan,” “may,” “will” and “could,” and similar expressions, identify forward-looking statements.

Sales estimates are based on the agreed framework and discussions with the customer and do not constitute binding purchase commitments. The annual estimates for 2027 and 2028 exclude the higher-capacity cell under development. Purchase orders for the near-term business described in this release have not yet been received. Actual sales and their timing depend on purchase orders, final pricing, deliveries and customer acceptance.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Risks include changes in customer demand or product requirements; pricing and input costs; expected orders that are not placed, or are delayed, reduced or cancelled; failure to agree on commercial terms; supplier performance and supply or logistics disruptions; delays or failures in the development, testing or customer qualification of the higher-capacity cell; competition; difficulties fulfilling orders, obtaining customer acceptance or collecting payment; foreign exchange fluctuations; customer concentration and credit risk; regulatory, economic and geopolitical changes; confidentiality restrictions and the need for customer consent before disclosing its identity; and other risks described in the Company’s reports filed with or furnished to the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit: https://en.cbak.com.cn/
Email: marketing@cbak.com.cn
LinkedIn: https://www.linkedin.com/company/cbakenergy
X: https://x.com/CBAKEnergy
Stocktwits: https://stocktwits.com/CBAK_Energy
Investor Relations
Email: ir@cbak.com.cn
Website: https://ir.cbak.com.cn/

CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) — Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, following the close of trading on the New York Stock Exchange.

Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, October 28, 2026, to discuss the company’s quarterly results and to provide an update on its business.

Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/v5gcs68f.

Participants may also register via teleconference at https://register-conf.media-server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call’s conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation’s largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed’s future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT: Michael D. Witzeman
(513) 762-6714

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surgery procedures.

“Tony’s addition comes at a pivotal moment as we transform our technology platform to scale and advance our patient-centric innovation for our highly differentiated personalized surgery business,” said Mike Cordonnier, Chairman and CEO. “As a true thought leader in the clinical deployment of AI-enabled surgical technologies at a large scale, I am thrilled to have Tony join our team and further elevate our market leadership position.”

Following the recent appointment of Rich Heppenstall as CFO and the promotion of Jeff Bertolini to COO, Tony joins an executive team that brings large scale experience to drive the next phase of growth. With Carlsmed’s proprietary technology platform for lumbar and cervical spine fusion, compelling clinical outcome data, and enhanced CMS reimbursement for all aprevo® lumbar fusion procedures effective today, the Company is well positioned to execute on its strategic growth priorities.

Dr. Jarc joins Carlsmed from Intuitive Surgical, Inc., where he most recently served as Vice President, Digital Products and Machine Learning Insights. During a tenure that spanned more than 15 years at Intuitive Surgical, he built the global AI organization from the ground up and pioneered clinical AI innovations including the case insights and My Intuitive. He earned a Bachelor of Science in Mechanical Engineering from Cornell University and holds both a Master of Science and a Ph.D. in Biomedical Engineering from Northwestern University.

“I am excited to join a Carlsmed team that has truly advanced spine surgery through its commitment to clinical research and deployment of technology, and generated meaningful evidence to support that these solutions improve patient outcomes,” added Dr. Jarc. “There is incredible opportunity to build on this foundation, both in the development of new products and the enhancement of our existing solutions. I look forward to working with Mike and the team to execute this vision.”

About Carlsmed

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed’s ability to execute on its strategic priorities, the potential and capabilities of Carlsmed’s current and future product offerings, Carlsmed’s growth prospects and market position, Carlsmed’s ability to improve its products and technology and develop new products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations
Stephanie Zhadkevich
Vice President, Head of Investor Relations
IR@Carlsmed.com

Media
LeAnn Burton
Senior Director, Brand Marketing
Marketing@Carlsmed.com

• Follows the launch of MoneyHero’s Hong Kong life insurance marketplace, supporting its strategy to grow high-margin verticals and deepen member engagement
• Features 13 plans from five insurers, Blue, Bowtie, FWD, OneDegree and Zurich, with coverage amounts of up to HK$4 million

HONG KONG, Oct. 01, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced the launch of critical illness insurance comparison in Hong Kong, further broadening the range of insurance products on its platform.

The launch is the first product delivery on the second-half 2026 product roadmap MoneyHero outlined on its second quarter 2026 earnings call. It will be integrated into and builds upon the life insurance marketplace introduced during the second quarter of 2026, supporting the continued expansion into high-margin verticals.

Critical illness insurance generally provides a lump-sum cash payout upon the diagnosis of a covered condition, such as cancer, heart attack, or stroke, giving policyholders financial flexibility to help cover medical costs, replace lost income, or support their recovery.

The marketplace will offer 13 plans from five insurers (in alphabetical order): Blue, Bowtie, FWD, OneDegree, and Zurich, ranging from entry-level protection to more comprehensive plans covering up to 71 conditions with coverage amounts of up to HK$4 million. Users can filter by age, gender, and smoker status for instant, personalised quotes, compare single-claim and multiple-claim options, and click through directly to their chosen insurer to complete the application.

With this launch, consumers can compare life, travel, and medical insurance products on MoneyHero’s platform, drawing on offerings from a range of established insurers. The addition of critical illness coverage reflects growing consumer demand for a simple, self-guided way to research and apply for protection products online.

“Critical illness insurance is an important addition to our insurance offerings, and one that reflects real demand we’re seeing from Hong Kong consumers,” said Danny Leung, Interim CEO and CFO. “Comparing critical illness insurance can feel overwhelming, with dense policy documents and unfamiliar terms. Our goal is to make the process simple and transparent, enabling customers to compare options from various insurers and choose the coverage that best fits their needs. This launch builds on the momentum of our life insurance marketplace and reinforces our strategy to grow our presence in high-margin verticals. It also lays the groundwork for the further protection and savings products in the coming quarters.”

Hong Kong consumers can start comparing plans today at https://www.moneyhero.com.hk/zh/insurance/critical-illness-insurance

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The Company also retains an equity stake in Malaysian fintech company, Jirnexu Pte. Ltd., parent company of Jirnexu Sdn.Bhd., the operator of Ringgit Plus, Malaysia’s largest operating B2C platform. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

Forward Looking Statements

This document includes “forward-looking statements” within the meaning of the United States federal securities laws and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this communication, including, but not limited to, statements as to the Company’s growth strategies, future results of operations and financial position, market size, industry trends and growth opportunities, are forward-looking statements. Undue reliance should not be placed upon the forward-looking statements.

For MoneyHero inquiries, please contact:

Investor Relations:
IR@MoneyHeroGroup.com

Media Relations:
Press@MoneyHeroGroup.com